Author: admin

The Gastroesophageal Reflux Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Gastroesophageal Reflux Disease Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Gastroesophageal Reflux Disease Market.

Some of the key takeaways from the Gastroesophageal Reflux Disease Pipeline Report:

• Companies across the globe are diligently working toward developing novel Gastroesophageal Reflux Disease treatment therapies with a considerable amount of success over the years. 
• Gastroesophageal Reflux Disease companies working in the treatment market are HK inno.N, Chong Kun Dang Pharmaceutical, Addpharma, Jeil Pharmaceuticals, Renexxion, Daewoong Pharmaceutical, and others, are developing therapies for the Gastroesophageal Reflux Disease treatment 
• Emerging Gastroesophageal Reflux Disease therapies in the different phases of clinical trials are- IN-C003, IN-C002, CKD-382, IN-C004, AD-214: , JP-1366, Naronapride, Fexuprazan, and others are expected to have a significant impact on the Gastroesophageal Reflux Disease market in the coming years.   
• In June 2022, Zydus Lifesciences was given permission by the Food and Drug Administration (FDA) to market Famotidine tablets in strengths of 20mg and 40mg. A histamine H2 receptor blocker called famotidine works by lowering stomach acid. The drug also relieves and prevents heartburn and other signs of acid reflux
• Fexuprazan is an experimental P-CAB used to treat EE, a chronic and progressive disease that affects millions of people in the United States. It’s intended to prevent proton pumps from secreting stomach acid. Proton pump inhibitors (PPIs), the current standard of care for EE, have been demonstrated to function more slowly whereas P-CABs block acid secretion more efficiently and long-term.

• The FDA has agreed to review the resubmitted New Drug Application (NDA) for vonoprazan, intended for managing erosive gastroesophageal reflux disease (GERD). A target date of November 17, 2023, under the Prescription Drug User Fee Act, has been established for the review process.

Gastroesophageal Reflux Disease Overview

The regurgitation of stomach contents into the oesophagus is what is known as gastroesophageal reflux disease (GERD), a chronic gastrointestinal ailment. It is one of the most often diagnosed digestive ailments in the US, with a prevalence of 20%, and it has a negative impact on quality of life and has a significant economic burden on both direct and indirect spending.

Get a Free Sample PDF Report to know more about Gastroesophageal Reflux Disease Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/gastroesophageal-reflux-disease-gerd-pipeline-insight

Emerging Gastroesophageal Reflux Disease Drugs Under Different Phases of Clinical Development Include:

• IN-C003: HK inno.N
• IN-C002: HK inno.N
• CKD-382: Chong Kun Dang Pharmaceutical
• IN-C004: HK inno.N
• AD-214: Addpharma
• JP-1366: Jeil Pharmaceuticals
• Naronapride: Renexxion
• Fexuprazan: Daewoong Pharmaceutical

Route of Administration

Gastroesophageal Reflux Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.
• Molecule Type

Molecule Type

Products have been categorized under various Molecule types, such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Gastroesophageal Reflux Disease Pipeline Therapeutics Assessment

• Gastroesophageal Reflux Disease Assessment by Product Type
• Gastroesophageal Reflux Disease By Stage and Product Type
• Gastroesophageal Reflux Disease Assessment by Route of Administration
• Gastroesophageal Reflux Disease By Stage and Route of Administration
• Gastroesophageal Reflux Disease Assessment by Molecule Type
• Gastroesophageal Reflux Disease by Stage and Molecule Type

DelveInsight’s Gastroesophageal Reflux Disease Report covers around 12+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Gastroesophageal Reflux Disease product details are provided in the report. Download the Gastroesophageal Reflux Disease pipeline report to learn more about the emerging Gastroesophageal Reflux Disease therapies

Some of the key companies in the Gastroesophageal Reflux Disease Therapeutics Market include:

Key companies developing therapies for Gastroesophageal Reflux Disease are – AstraZeneca, Aurobindo Pharma Limited, Cadila Pharmaceuticals Limited, Camber Pharmaceuticals Inc., CHEPLAPHARM Arzneimittel GmbH, Daewoong Pharmaceutical Co., Ltd, Eisai Co. Ltd., EndoStim, Inc., GlaxoSmithKline PLC, Ironwood Pharmaceuticals, Inc., Jeil Pharmaceutical Co., Ltd., Johnson & Johnson Services, Inc., Novartis AG, Phathom Pharmaceuticals Inc., Reckitt Benckiser Group PLC, Sebela Pharmaceuticals, SFJ Pharmaceuticals Group, SRS Life Sciences Pte. Ltd., Sun Pharmaceutical Industries Limited, Takeda Pharmaceutical Company Ltd, Teva Pharmaceuticals Industries Limited, and others.

Gastroesophageal Reflux Disease Pipeline Analysis:

The Gastroesophageal Reflux Disease pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Gastroesophageal Reflux Disease with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Gastroesophageal Reflux Disease Treatment.
• Gastroesophageal Reflux Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Gastroesophageal Reflux Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Gastroesophageal Reflux Disease market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Gastroesophageal Reflux Disease drugs and therapies

Gastroesophageal Reflux Disease Pipeline Market Drivers

• Rising incidence of heartburn across the globe, technological advancements that allow for speedier diagnosis, are some of the important factors that are fueling the Gastroesophageal Reflux Disease Market.

Gastroesophageal Reflux Disease Pipeline Market Barriers

• However, loss of patent protection of several leading drugs, lack of approved therapies, and other factors are creating obstacles in the Gastroesophageal Reflux Disease Market growth.

Scope of Gastroesophageal Reflux Disease Pipeline Drug Insight    

• Coverage: Global
• Key Gastroesophageal Reflux Disease Companies:  HK inno.N, Chong Kun Dang Pharmaceutical, Addpharma, Jeil Pharmaceuticals, Renexxion, Daewoong Pharmaceutical, and others
• Key Gastroesophageal Reflux Disease Therapies: IN-C003, IN-C002, CKD-382, IN-C004, AD-214: , JP-1366, Naronapride, Fexuprazan, and others
• Gastroesophageal Reflux Disease Therapeutic Assessment: Gastroesophageal Reflux Disease current marketed and Gastroesophageal Reflux Disease emerging therapies
• Gastroesophageal Reflux Disease Market Dynamics: Gastroesophageal Reflux Disease market drivers and Gastroesophageal Reflux Disease market barriers 

Request for Sample PDF Report for Gastroesophageal Reflux Disease Pipeline Assessment and clinical trials

Table of Contents

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Gastroesophageal Reflux Disease Pipeline Assessment: FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, Therapeutic Analysis, and Growth Prospects | HK inno.N, Chong Kun Dang Pharma

The Choroideremia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Choroideremia Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Choroideremia Market.

Some of the key takeaways from the Choroideremia Pipeline Report:

• Companies across the globe are diligently working toward developing novel Choroideremia treatment therapies with a considerable amount of success over the years. Choroideremia Key players such as – Curative Biotech, 4D Molecular Therapeutics, Spark Therapeutics, NightstaRx Ltd., and others, are developing therapies for the Choroideremia treatment 
• Choroideremia Emerging therapies such as – Metformin, 4D-110, SPK-7001, BIIB111, and others are expected to have a significant impact on the Choroideremia market in the coming years.   
• In November 2023, Brian Strem, CEO of Kiora Pharmaceuticals, spoke with Steve Darling from Proactive to announce the company’s strategy to expand the clinical exploration of KIO-301, a therapy aimed at treating different inherited retinal conditions. This expansion entails launching a controlled, double-masked, randomized Phase 2 trial with escalating doses.

Choroideremia Overview

Choroideremia is a rare genetic disorder of vision that is more common in man. It is an X-linked recessive condition that leads to gradual degradation of choroid, retinal pigment epithelium (RPE), and photoreceptors. Female are mostly the carriers and mostly unaffected, even so they can experience minor symptoms, such as blurred vision in later stages of their life 

Get a Free Sample PDF Report to know more about Choroideremia Pipeline Therapeutic Assessment:

https://www.delveinsight.com/report-store/choroideremia-pipeline-insight

Route of Administration

Choroideremia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Molecule Type

Products have been categorized under various Molecule types, such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy 

Choroideremia Pipeline Therapeutics Assessment

• Choroideremia Assessment by Product Type
• Choroideremia By Stage and Product Type
• Choroideremia Assessment by Route of Administration
• Choroideremia By Stage and Route of Administration
• Choroideremia Assessment by Molecule Type
• Choroideremia by Stage and Molecule Type

DelveInsight’s Choroideremia Report covers around products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Choroideremia product details are provided in the report. Download the Choroideremia pipeline report to learn more about the emerging Choroideremia therapies

Choroideremia Pipeline Analysis:

The Choroideremia pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Choroideremia with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Choroideremia Treatment.
• Choroideremia key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Choroideremia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Choroideremia market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Some of the key companies in the Choroideremia Therapeutics Market include:

Key companies developing therapies for Choroideremia are – NightstaRx Ltd/Biogen, 4D Molecular Therapeutics, Curative Biotech, Therapeutics, Spark therapeutics/Roche, and others. 

Emerging Choroideremia Drugs Under Different Phases of Clinical Development Include:

• Metformin: Curative Biotech
• 4D-110: 4D Molecular Therapeutics
• SPK-7001: Spark Therapeutics
• BIIB111: NightstaRx Ltd.

Download Sample PDF Report to know more about Choroideremia drugs and therapies 

Scope of Choroideremia Pipeline Drug Insight    

• Coverage: Global
• Key Choroideremia Companies: Curative Biotech, 4D Molecular Therapeutics, Spark Therapeutics, NightstaRx Ltd., and others
• Key Choroideremia Therapies: Metformin, 4D-110, SPK-7001, BIIB111, and others
• Choroideremia Therapeutic Assessment: Choroideremia current marketed and Choroideremia emerging therapies
• Choroideremia Market Dynamics: Choroideremia market drivers and Choroideremia market barriers 

Request for Sample PDF Report for Choroideremia Pipeline Assessment and clinical trials

Table of Contents

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

About DelveInsight 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Choroideremia Pipeline Assessment | In-depth Insights into the Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Clinical Trials, and Treatment Outlook | Curative Biotech, 4D Molecular Therapeutics

The Hemophilia A Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Hemophilia A Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Hemophilia A Market.

Some of the key takeaways from the Hemophilia A Pipeline Report: 

• Companies across the globe are diligently working toward developing novel Hemophilia A treatment therapies with a considerable amount of success over the years. 
• Hemophilia A companies working in the treatment market are Generation Bio, Poseida Therapeutics, Expression Therapeutics, Chugai Pharmaceutical, ASC Therapeutics, Ascension, Staidson (Beijing) Biopharmaceuticals, Chia Tai Tianqing Pharmaceutical Group, Novo Nordisk, Pfizer, and others, are developing therapies for the Hemophilia A treatment 
• Emerging Hemophilia A therapies in the different phases of clinical trials are- Research program: Gene Therapies, P-FVIII-101, ET3 lentiviral gene therapy, NXT007, ASC618, SelectAte, STSP-0601, TQG 203, Mim8, Giroctocogene fitelparvovec, and others are expected to have a significant impact on the Hemophilia A market in the coming years.
• In December 2023, Roche has released preliminary analysis findings from the Phase III HAVEN 7 clinical trial, demonstrating the efficacy of Hemlibra (emicizumab), a bispecific antibody targeting factor IXa and factor X, in infants suffering from severe hemophilia A but lacking factor VIII inhibitors.
• In January 2023: worldwide biotechnology business BioMarin Pharmaceutical Inc., committed to improving lives through genetic research, released encouraging findings from its ongoing worldwide Phase 3 GENEr8-1 study of ROCTAVIANTM (valoctocogene roxaparvovec) after more than three years of follow-up. An experimental one-time gene therapy is being used to treat adults with severe hemophilia A. With 134 participants, it is the largest and most extensive global Phase 3 study for any gene treatment in hemophilia.In February 2023, For adults and children with hemophilia A, the US FDA approved ALTUVIIIO (efanesoctocog alfa) as a factor VIII replacement medication. For adults and children with hemophilia A, ALTUVIIIO is recommended for perioperative management (surgery), routine prophylaxis, and on-demand medication to control bleeding episodes.
• In September 2022, Reopening recruitment for the Phase III AFFINE trial, which is assessing giroctocogene fitelparvovec, is a joint announcement from Pfizer and Sangamo Therapeutics.
• In August 2022, For the treatment of severe hemophilia A (congenital Factor VIII deficiency) in adult patients without a history of Factor VIII inhibitors and without detectable antibodies to adeno-associated virus serotype 5, the European Commission (EC) granted conditional marketing permission to ROCTAVIAN gene therapy.

Hemophilia A Overview

A genetic bleeding illness called hemophilia A, or classical hemophilia, is brought on by low amounts of a blood protein called factor VIII. Hemophilia A patients will bleed more profusely following an injury, procedure, or surgery.

Get a Free Sample PDF Report to know more about Hemophilia A Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/hemophilia-a-pipeline-insight-2020

Emerging Hemophilia A Drugs Under Different Phases of Clinical Development Include:

• Research program: Gene Therapies: Generation Bio
• P-FVIII-101: Poseida Therapeutics
• ET3 lentiviral gene therapy: Expression Therapeutics
• NXT007: Chugai Pharmaceutical
• ASC618: ASC Therapeutics
• SelectAte: Ascension
• STSP-0601: Staidson (Beijing) Biopharmaceutic als
• TQG 203: Chia Tai Tianqing Pharmaceutical Group
• Mim8: Novo Nordisk
• Giroctocogene fitelparvovec: Pfizer

Hemophilia A Route of Administration

Hemophilia A pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Hemophilia A Molecule Type

Hemophilia A Products have been categorized under various Molecule types, such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy 

Hemophilia A Pipeline Therapeutics Assessment

• Hemophilia A Assessment by Product Type
• Hemophilia A By Stage and Product Type
• Hemophilia A Assessment by Route of Administration
• Hemophilia A By Stage and Route of Administration
• Hemophilia A Assessment by Molecule Type
• Hemophilia A by Stage and Molecule Type

DelveInsight’s Hemophilia A Report covers around 45+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Hemophilia A product details are provided in the report. Download the Hemophilia A pipeline report to learn more about the emerging Hemophilia A therapies

Some of the key companies in the Hemophilia A Therapeutics Market include:

Key companies developing therapies for Hemophilia A are – ApcinteX, ASC Therapeutics, Ultragenix Pharmaceutical, BioMarin Pharmaceutical, CSL Behring, Freeline Therapeutics, Genentech, Inc., Novo Nordisk, Pfizer, Sanofi, Shire, Spark Therapeutics, Amarna therapeutics, Asklepios BioPharmaceutical, Bayer, Belief Biomed, Bioverativ, Catalyst Biosciences, Centessa Pharmaceuticals, Chameleon Biosciences, Chia Tai Tianqing Pharmaceutical Group, Expression Therapeutics, GC Pharma, GeneVentiv, Intellia tx, OPKO Health, Sangamo Therapeutics, Staidson Beijing BioPharmaceuticals, UBI Pharma, uniQure, and others.

Hemophilia A Pipeline Analysis:

The Hemophilia A pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Hemophilia A with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hemophilia A Treatment.
• Hemophilia A key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Hemophilia A Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hemophilia A market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Hemophilia A drugs and therapies

Hemophilia A Pipeline Market Drivers

• Increasing number of hemophilic patients worldwide, increasing development of novel therapies, increasing diagnostic rate are some of the important factors that are fueling the Hemophilia A Market.

Hemophilia A Pipeline Market Barriers

• However, side effects associated with the plasma derived products, high cost of recombinant products and other factors are creating obstacles in the Hemophilia A Market growth.

Scope of Hemophilia A Pipeline Drug Insight    

• Coverage: Global
• Key Hemophilia A Companies: Generation Bio, Poseida Therapeutics, Expression Therapeutics, Chugai Pharmaceutical, ASC Therapeutics, Ascension, Staidson (Beijing) Biopharmaceuticals, Chia Tai Tianqing Pharmaceutical Group, Novo Nordisk, Pfizer, and others
• Key Hemophilia A Therapies: Research program: Gene Therapies, P-FVIII-101, ET3 lentiviral gene therapy, NXT007, ASC618, SelectAte, STSP-0601, TQG 203, Mim8, Giroctocogene fitelparvovec, and others
• Hemophilia A Therapeutic Assessment: Hemophilia A current marketed and Hemophilia A emerging therapies
• Hemophilia A Market Dynamics: Hemophilia A market drivers and Hemophilia A market barriers 

Request for Sample PDF Report for Hemophilia A Pipeline Assessment and clinical trials

Table of Contents

1. Hemophilia A Report Introduction

2. Hemophilia A Executive Summary

3. Hemophilia A Overview

4. Hemophilia A- Analytical Perspective In-depth Commercial Assessment

5. Hemophilia A Pipeline Therapeutics

6. Hemophilia A Late Stage Products (Phase II/III)

7. Hemophilia A Mid Stage Products (Phase II)

8. Hemophilia A Early Stage Products (Phase I)

9. Hemophilia A Preclinical Stage Products

10. Hemophilia A Therapeutics Assessment

11. Hemophilia A Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Hemophilia A Key Companies

14. Hemophilia A Key Products

15. Hemophilia A Unmet Needs

16 . Hemophilia A Market Drivers and Barriers

17. Hemophilia A Future Perspectives and Conclusion

18. Hemophilia A Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Hemophilia A Pipeline Drugs Analysis Report, 2024 Updates: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Genentech, Novo Nordisk, Pfizer, Sanofi, Shire, ApcinteX, CSL Behring

The Neuromyelitis Optica Spectrum Disorder Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Neuromyelitis Optica Spectrum Disorder Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Neuromyelitis Optica Spectrum Disorder Market.

Some of the key takeaways from the Neuromyelitis Optica Spectrum Disorder Pipeline Report:

• Companies across the globe are diligently working toward developing novel Neuromyelitis Optica Spectrum Disorder treatment therapies with a considerable amount of success over the years. 
• Neuromyelitis Optica Spectrum Disorder companies working in the treatment market are Harbour BioMed, Reistone Biopharma, RemeGen, ENDECE, Aeterna Zentaris, Shanghai Pharmaceuticals Holding Co., Ltd., Guangzhou Lupeng Pharmaceutical Company LTD., Alexion Pharmaceuticals, and others, are developing therapies for the Neuromyelitis Optica Spectrum Disorder treatment 
• Emerging Neuromyelitis Optica Spectrum Disorder therapies in the different phases of clinical trials are- HBM9161, SHR1459, Telitacicept, NDC-1308, AIM Biologicals, B001, LP-168, Ravulizumab, and others are expected to have a significant impact on the Neuromyelitis Optica Spectrum Disorder market in the coming years.   
• In March 2024, Alexion Pharmaceuticals Ultomiris gained FDA approval for treating adults with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder. The decision stemmed from encouraging outcomes in the phase 3 CHAMPION-NMOSD trial, comparing Ultomiris (ravulizumab-cwvz), a prolonged-acting C5 complement inhibitor, with a placebo arm from the pivotal Soliris (eculizumab) PREVENT clinical trial.
• In June 2022, Alexion Pharmaceuticals commenced a Phase II/III clinical trial, employing an open-label, historical-controlled, single-arm, multicenter approach to assess the effectiveness, pharmacokinetics, pharmacodynamics, and safety of ravulizumab in children and adolescents diagnosed with Neuromyelitis Optica Spectrum Disorder (NMOSD) who test positive for aquaporin-4 antibodies (AQP4-Ab [+]).
• In June 2022, The Brazilian Health Regulatory Agency (ANVISA) granted approval for UPLIZNA as a standalone treatment intended for adult patients diagnosed with Neuromyelitis Optica Spectrum Disorder (NMOSD) who exhibit a positive test result for the AQP4-IgG biomarker.
• In May 2022, The European Commission granted approval to UPLIZNA, a medication created by Horizon Therapeutics, as a standalone treatment for adult individuals diagnosed with neuromyelitis optica spectrum disorder (NMOSD). This approval encompasses all adult NMOSD patients, irrespective of their AQP4-IgG biomarker test results.

Neuromyelitis Optica Spectrum Disorder Overview

Neuromyelitis Optica Spectrum Disorder (NMOSD), also recognized as Devic disease, is a persistent condition affecting the brain and spinal cord, primarily characterized by inflammation in the optic nerve (optic neuritis) and the spinal cord (myelitis). The occurrence and frequency of NMOSD vary, with reported rates ranging from 0.05–0.40 and 0.52–4.4 per 100,000 individuals, respectively.

Get a Free Sample PDF Report to know more about Neuromyelitis Optica Spectrum Disorder Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/neuromyelitis-optica-spectrum-disorder-nmosd-pipeline-insight

Emerging Neuromyelitis Optica Spectrum Disorder Drugs Under Different Phases of Clinical Development Include:

• HBM9161: Harbour BioMed
• SHR1459: Reistone Biopharma
• Telitacicept: RemeGen
• NDC-1308: ENDECE
• AIM Biologicals: Aeterna Zentaris
• B001: Shanghai Pharmaceuticals Holding Co., Ltd.
• LP-168: Guangzhou Lupeng Pharmaceutical Company LTD.
• Ravulizumab: Alexion Pharmaceuticals

Neuromyelitis Optica Spectrum Disorder Route of Administration

Neuromyelitis Optica Spectrum Disorder pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Intravenous
• Oral
• Subcutaneous
• Molecule Type

Neuromyelitis Optica Spectrum Disorder Molecule Type

Neuromyelitis Optica Spectrum Disorder Products have been categorized under various Molecule types, such as

• Immunoglobulin
• Monoclonal antibodies
• Protein
• Recombinant fusion proteins
• Small molecules
• Vaccine
• Product Type

Neuromyelitis Optica Spectrum Disorder Pipeline Therapeutics Assessment

• Neuromyelitis Optica Spectrum Disorder Assessment by Product Type
• Neuromyelitis Optica Spectrum Disorder By Stage and Product Type
• Neuromyelitis Optica Spectrum Disorder Assessment by Route of Administration
• Neuromyelitis Optica Spectrum Disorder By Stage and Route of Administration
• Neuromyelitis Optica Spectrum Disorder Assessment by Molecule Type
• Neuromyelitis Optica Spectrum Disorder by Stage and Molecule Type

DelveInsight’s Neuromyelitis Optica Spectrum Disorder Report covers around 15+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Neuromyelitis Optica Spectrum Disorder product details are provided in the report. Download the Neuromyelitis Optica Spectrum Disorder pipeline report to learn more about the emerging Neuromyelitis Optica Spectrum Disorder therapies

Some of the key companies in the Neuromyelitis Optica Spectrum Disorder Therapeutics Market include:

Key companies developing therapies for Neuromyelitis Optica Spectrum Disorder are – Hoffmann-La Roche Ltd, Horizon Therapeutics plc, TG Therapeutics, Opexa Therapeutics, Mitsubishi Tanabe Pharma, Remegen, Teva Pharma, TG Therapeutics, Astrazeneca, Harbour Biomed, and others.

Neuromyelitis Optica Spectrum Disorder Pipeline Analysis:

The Neuromyelitis Optica Spectrum Disorder pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Neuromyelitis Optica Spectrum Disorder with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Neuromyelitis Optica Spectrum Disorder Treatment.
• Neuromyelitis Optica Spectrum Disorder key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Neuromyelitis Optica Spectrum Disorder Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Neuromyelitis Optica Spectrum Disorder market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Neuromyelitis Optica Spectrum Disorder drugs and therapies

Neuromyelitis Optica Spectrum Disorder Pipeline Market Drivers

• Increase in NMOSD prevalence, rising awareness among general population about NMOSD, emergence of novel therapies are some of the important factors that are fueling the Neuromyelitis Optica Spectrum Disorder Market.

Neuromyelitis Optica Spectrum Disorder Pipeline Market Barriers

• However, dearth of skilled professionals and lack of healthcare infrastructure in developing economies, high costs for NMOSD treatment and other factors are creating obstacles in the Neuromyelitis Optica Spectrum Disorder Market growth.

Scope of Neuromyelitis Optica Spectrum Disorder Pipeline Drug Insight    

• Coverage: Global
• Key Neuromyelitis Optica Spectrum Disorder Companies: Harbour BioMed, Reistone Biopharma, RemeGen, ENDECE, Aeterna Zentaris, Shanghai Pharmaceuticals Holding Co., Ltd., Guangzhou Lupeng Pharmaceutical Company LTD., Alexion Pharmaceuticals, and others
• Key Neuromyelitis Optica Spectrum Disorder Therapies: HBM9161, SHR1459, Telitacicept, NDC-1308, AIM Biologicals, B001, LP-168, Ravulizumab, and others
• Neuromyelitis Optica Spectrum Disorder Therapeutic Assessment: Neuromyelitis Optica Spectrum Disorder current marketed and Neuromyelitis Optica Spectrum Disorder emerging therapies
• Neuromyelitis Optica Spectrum Disorder Market Dynamics: Neuromyelitis Optica Spectrum Disorder market drivers and Neuromyelitis Optica Spectrum Disorder market barriers 

Request for Sample PDF Report for Neuromyelitis Optica Spectrum Disorder Pipeline Assessment and clinical trials

Table of Contents

1. Neuromyelitis Optica Spectrum Disorder Report Introduction

2. Neuromyelitis Optica Spectrum Disorder Executive Summary

3. Neuromyelitis Optica Spectrum Disorder Overview

4. Neuromyelitis Optica Spectrum Disorder- Analytical Perspective In-depth Commercial Assessment

5. Neuromyelitis Optica Spectrum Disorder Pipeline Therapeutics

6. Neuromyelitis Optica Spectrum Disorder Late Stage Products (Phase II/III)

7. Neuromyelitis Optica Spectrum Disorder Mid Stage Products (Phase II)

8. Neuromyelitis Optica Spectrum Disorder Early Stage Products (Phase I)

9. Neuromyelitis Optica Spectrum Disorder Preclinical Stage Products

10. Neuromyelitis Optica Spectrum Disorder Therapeutics Assessment

11. Neuromyelitis Optica Spectrum Disorder Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Neuromyelitis Optica Spectrum Disorder Key Companies

14. Neuromyelitis Optica Spectrum Disorder Key Products

15. Neuromyelitis Optica Spectrum Disorder Unmet Needs

16 . Neuromyelitis Optica Spectrum Disorder Market Drivers and Barriers

17. Neuromyelitis Optica Spectrum Disorder Future Perspectives and Conclusion

18. Neuromyelitis Optica Spectrum Disorder Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Neuromyelitis Optica Spectrum Disorder Pipeline and Clinical Trials Assessment, 2024 Updates: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Hoffmann-La Roche Ltd, Horizon